Effect of sacubitril valsartan combined with ezetimibe and metoprolol in the treatment of elderly patients with coronary heart disease and its influences on myocardial injury markers,TGF-β1 and ICAM-1 levels
Objective To investigate the effect of sacubitril valsartan combined with ezetimibe and metoprolol in the treatment of elderly patients with coronary heart disease(CHD)and its influences on myocardial injury markers,transforming growth factor-β1(TGF-β1)and intercellular cell adhesion molecule-1(ICAM-1)levels.Methods A total of 120 elderly CHD patients admitted in our hospital from March 2020 to January 2022 were selected as the research objects and divided into control group and observation group by random number table method,with 60 cases in each group.The control group was treated with ezetimibe and metoprolol,and the observation group was treated with sacubitril valsartan on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).Before treatment,there were no significant differences in the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI)and creatine kinase isoenzyme MB(CK-MB)between the two groups(P>0.05);after treatment,the levels of NT-proBNP,cTnI and CK-MB in the observation group were lower than those in the control group(P<0.05).Before treatment,there were no significant differences in the levels of TGF-β1 and ICAM-1 between the two groups(P>0.05);after treatment,the level of TGF-β1 in the observation group was higher than that in the control group,and the level of ICAM-1 was lower than that in the control group(P<0.05).Conclusion Sacubitril valsartan combined with ezetimibe and metoprolol in the treatment of elderly CHD can not only improve the therapeutic effect,reduce the levels of myocardial injury markers,but also regulate the expression of TGF-β1 and ICAM-1,which is worthy of promotion.
万方数据
维普
